CombinatoRx and Cystic Fibrosis Foundation Therapeutics Enter into a Collaboration

Development of Novel Therapeutics Built from Synergistic Drug Combinations

07-Jun-2006

CombinatoRx, Incorporated and cystic fibrosis Foundation Therapeutics (CFFT) entered into a collaboration to discover and develop novel therapeutics built from synergistic drug combinations to treat cystic fibrosis (CF). Under the terms of the agreement, CFFT will award CombinatoRx up to $13.8 million in research expenses and will also fund up to 75% of clinical development expenses through Phase 2a on the first potential product candidate, provided both parties agree to commence clinical development. In addition, CombinatoRx will retain full worldwide commercialization rights, receive payments upon successful completion of certain clinical and regulatory milestones, and own new intellectual property generated during the collaboration. CFFT will be eligible to receive royalties from CombinatoRx on net sales of any approved products.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance